The FDA Announced a Recall of This Children's Cough Syrup Dating Back to 2022
The five affected lots were distributed in the US both online and in retail stores from Dec. 14, 2022, to June 4, 2025. The lot numbers are 0039, 0545, 0640, 0450 and 1198, while the impacted expiration dates extend to December 2026.
The FDA reports that "no serious adverse events have been reported to date."
This cough syrup contains three ingredients: honey, purified water and a natural preservative.
Amazon
If you purchased a Little Remedies Honey Cough Syrup that has been recalled, stop using it as soon as possible. If your child has experienced any issues that may be related to this product, contact their doctor. For reimbursement, you can email Medtech at medicalaffairs@prestigebrands.com, contact via its website at https://www.prestigebrands.com/contact or by phone at (800) 754-8853, Monday through Friday from 8:30 a.m. to 5:30 p.m. Eastern time.
Any reactions or quality issues can be reported to the FDA's MedWatch Adverse Event Reporting program.
What is Bacillus cereus?
The FDA reports that Bacillus cereus or B. cereus is a bacterium that can cause two types of foodborne illnesses.
The first type can start one to six hours after consumption of the contaminated food or drink. Symptoms include: stomach cramps, vomiting and nausea.
The second type of foodborne illness that Bacillus cereus causes can occur eight to 16 hours after consumption. Its symptoms are diarrhea and stomach cramps.
"Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death," explains the FDA.
If your child is demonstrating any of these symptoms related to the consumption of Little Remedies Honey Cough Syrup, contact their doctor immediately.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing stocks on Wednesday. ImmunityBio soared by 14.17 percent on Wednesday to close at $2.82 apiece as investors cheered promising early findings from its ongoing trial (QUILT-106) to treat a rare blood cancer type with its therapy candidate. In a statement, ImmunityBio, Inc. (NASDAQ:IBRX) said the first phase of QUILT-106 showed highly promising results in the first two patients with Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. The trial aims to evaluate the safety and efficacy of the cell therapy alone, as well as when it is combined with an existing drug called rituximab. According to ImmunityBio, Inc. (NASDAQ:IBRX), both patients tolerated the therapy candidate without any significant side effects. Notably, all infusions were administered in an outpatient setting. Copyright: katrintimoff / 123RF Stock Photo 'One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date,' ImmunityBio, Inc. (NASDAQ:IBRX) said. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
HealthPartners launches simple, copay-only health plan
Simplica NextGen Copay plan provides costs up front, lets members compare providers, and can save employers up to 15% compared to other plan options. BLOOMINGTON, Minn., August 14, 2025--(BUSINESS WIRE)--HealthPartners is launching a variable copay benefit plan that aims to provide unparalleled transparency of cost and coverage to members. HealthPartners Simplica NextGen Copay health plan has no deductible or coinsurance for in-network care, and members see what they'll pay up front before scheduling. Copay amounts for specific services at each hospital or clinic vary based on the quality and affordability of the care delivered. A key feature of the plan is the personalized digital experience fully integrated within a member's HealthPartners account. Using HealthPartners' Find Care tool, members can search by condition, provider or service; compare care options; and see their exact copay before scheduling. Members pay less when they choose care with better outcomes. "We developed Simplica in response to the growing demand for more predictable benefits," says Andrea Walsh, HealthPartners president and CEO. "This plan gives members the cost clarity and ease they expect from their health plan and guides them in making informed decisions about where to get the care they need." For example, the copay for an office visit will range from $20 to $150 depending upon the plan option, care site and service. Most same day labs and x-rays are bundled into the copay – helping reduce unexpected costs. Services that may require a separate copay are also visible through the Find Care digital experience. In addition, many virtual care options are covered at a $0 copay. The plan will launch Jan. 1, 2026, and is initially available to large-group, self-insured employers in the Twin Cities metro and surrounding counties. Simplica can save companies up to 15% in claim costs and that translates into savings for employees. "Unlike third-party platforms or standalone applications, Simplica delivers one seamless experience that makes it easier for members and employers to understand and manage costs," says Moe Suleiman, HealthPartners senior vice president of health solutions. "This plan ties copays to provider value, guides members in real time, and delivers the digital-first convenience today's workforce expects." For more information, visit the Simplica NextGen Copay website. About HealthPartners HealthPartners is a nonprofit organization with a mission of improving health and well-being in partnership with its members, patients and community. An integrated system of care and coverage since its founding in 1957, HealthPartners operates hospitals and clinics, health plans, and a research and education institute. The Minneapolis-based organization serves more than 1.3 million patients in Minnesota and Wisconsin and 1.7 million medical and dental health plan members nationwide. For more information, visit View source version on Contacts Amanda
The Hill
10 minutes ago
- The Hill
Mars says M&M's, Starbursts without synthetic dyes coming in 2026
Video above: FDA announces in April 2025 that it will phase out food dyes. (NEXSTAR) — While several other food companies had confirmed they would drop artificial food dyes in response to a mission set forth by Health and Human Services Secretary Robert F. Kennedy Jr. earlier this summer, Mars Wrigley was considered a holdout. That quietly changed late last month. In a late-July statement, which was first reported by Bloomberg on Thursday, Mars Wrigley North America announced it plans to release 'product options' made without artificial dyes in 2026. These options without synthetic dyes will be available only across four of its brands to start, according to the statement: M&M's, Skittles Original, Extra Gum Spearmint, and Starburst Original fruit chews. They'll be available to purchase online throughout the U.S. A spokesperson confirmed to Nexstar that the 'choice products' without artificial dyes will be additions to the current brands. They declined to say whether currently available products will be affected by the dye changes. AT&T reached a $177M settlement over data breaches: Will you get a payment? Mars did not immediately respond to Nexstar's request for additional information, like whether these options will replace others within each brand's portfolio, or if currently available products would be otherwise impacted. 'When we have identified fully effective, scalable solutions across the entire portfolio, we will share additional item commitments and timelines,' the company said in its statement. In April, Food and Drug Administration Commissioner Marty Makary said the agency would move to eliminate several synthetic dyes by the end of next year. That includes Green 3, Red 40, Yellow 5, Yellow 6, Blue 1, and Blue 2. Red 3 was set to be banned in food by 2027 because it caused cancer in laboratory rats; the FDA called for that deadline to move up. The FDA has been relying on companies voluntarily ditching the aforementioned dyes, but does plan to establish a standard and timeline for the food industry to switch to natural alternatives and revoke authorization for dyes not in production. Additionally, the FDA said it would authorize four new natural color additives. Several food manufacturers have already announced plans to ditch synthetic colors. That includes General Mills, Pepsico, ConAgra, Nestle, McCormick, Tyson Foods, Sam's Club, JM Smucker, Hershey, Kraft Heinz, and dozens of companies that make ice cream and frozen dairy desserts. Mars, however, was a holdout as of mid-July. The company now stands to be among the first to have products without artificial dyes available. Artificial dyes are used widely in U.S. foods. In Canada and in Europe — where synthetic colors are required to carry warning labels — manufacturers mostly use natural substitutes. Several states, including California and West Virginia, have passed laws restricting the use of artificial colors in foods. Health advocates have long called for the removal of artificial dyes from foods, citing mixed studies indicating they can cause neurobehavioral problems, including hyperactivity and attention issues, in some children. The FDA has maintained that the approved dyes are safe and that 'the totality of scientific evidence shows that most children have no adverse effects when consuming foods containing color additives.' The FDA currently allows 36 food color additives, including eight synthetic dyes. Removing dyes from the food supply will not address the chief health problems that plague Americans, said Susan Mayne, a Yale University chronic disease expert and former director of the FDA's food center. 'With every one of their announcements, they're focusing in on something that's not going to accomplish what they say it is,' Mayne said of Kennedy's initiatives. 'Most of these food dyes have been in our food supply for 100 years. … So why aren't they driving toward reductions in things that do drive chronic disease rates?'
